? PROJECT 2 The goal of our Program Project is to discover the biological transformations that occur in the brain during the perimenopausal transition that can result in phenotypes predictive of risk for development of AD pathology. Our focus is on the primary genetic risk factor for late-onset AD, the ?4 allele of apolipoprotein E (ApoE4), and how it is disproportionally affects AD risk in women. In particular, we will investigate interactions between several significant risk factors for AD: age, the ApoE4, and female sex. In Project 2, our specific emphasis is how ApoE4 interacts with female sex, perimenopause and adiposity to cooperatively drive development of AD pathology. Perimenopause initiates the age-related depletion of ovarian hormones in women. Perimenopause is also linked with increases in body weight and adiposity that often lead to obesity, an established risk factor for the development of AD. Significantly, adiposity and obesity are not only regulated by ovarian hormones, but also are known to impair bioenergetics and increase inflammation. Thus, perimenopause creates a dangerous convergence of AD risk factors in middle-aged women that we hypothesize is exacerbated by ApoE4. We hypothesize that the central unifying link between AD, ApoE, obesity and estrogen is inflammation. Pro- inflammatory pathways can function as critical driving forces in AD pathogenesis, are elevated by both ApoE4 genotype and obesity, and are inhibited by estrogen. To investigate these relationships, we propose three specific aims that are highly collaborative across all Cores and Projects.
Specific Aim 1 : ApoE genotype interactions in the regulation of inflammation and Alzheimer's pathways. We will compare the effects of ApoE alleles on expression of AD- and inflammation-related genes, AD neuropathology, metabolism, and cognition Specific Aim 2: Obesity and ApoE genotype interactions with female sex in the regulation of inflammation and Alzheimer's pathways. We will determine how ApoE status interacts with obesity in the regulation of AD- and inflammation-related pathways, AD neuropathology, metabolism and cognition.
Specific Aim 3 : Hormone interventions for protection against inflammation and Alzheimer's pathways associated with ApoE genotype, obesity and perimenopause. We will evaluate the efficacy of estrogen-based hormone therapies in attenuating the effects of ApoE4, in the presence and absence of obesity, during both perimenopause and late menopause.

Public Health Relevance

? PROJECT 2 Alzheimer's disease disproportionatley affects women due to the cooperative effects of the genetic risk factor APOE4, hormone depletion at perimenopause, natural aging, and environmental riisk factors including obesity. This proposal will define interactive relationships among these factors and how they are affected by hormone interventions, basic science information that is essential for understanding Alzheimer's risk in women.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG026572-11
Application #
9074569
Study Section
Special Emphasis Panel (ZAG1-ZIJ-G (J3))
Project Start
Project End
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
11
Fiscal Year
2016
Total Cost
$284,871
Indirect Cost
$13,375
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Geifman, Nophar; Kennedy, Richard E; Schneider, Lon S et al. (2018) Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions. Alzheimers Res Ther 10:4
Walters, Michelle J; Sterling, Joanna; Quinn, Crystal et al. (2018) Associations of lifestyle and vascular risk factors with Alzheimer's brain biomarker changes during middle age: a 3-year longitudinal study in the broader New York City area. BMJ Open 8:e023664
Mosconi, Lisa; Brinton, Roberta Diaz (2018) How would we combat menopause as an Alzheimer's risk factor? Expert Rev Neurother 18:689-691
Mosconi, Lisa; Walters, Michelle; Sterling, Joanna et al. (2018) Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer's disease: a cross-sectional study of middle-aged adults from the broader New York City area. BMJ Open 8:e019362
Moser, V Alexandra; Uchoa, Mariana F; Pike, Christian J (2018) TLR4 inhibitor TAK-242 attenuates the adverse neural effects of diet-induced obesity. J Neuroinflammation 15:306
Berkowitz, C L; Mosconi, L; Rahman, A et al. (2018) Clinical Application of APOE in Alzheimer's Prevention: A Precision Medicine Approach. J Prev Alzheimers Dis 5:245-252
Gahm, Jin Kyu; Shi, Yonggang; Alzheimer’s Disease Neuroimaging Initiative (2018) Riemannian metric optimization on surfaces (RMOS) for intrinsic brain mapping in the Laplace-Beltrami embedding space. Med Image Anal 46:189-201
Riedel, Brandalyn C; Daianu, Madelaine; Ver Steeg, Greg et al. (2018) Uncovering Biologically Coherent Peripheral Signatures of Health and Risk for Alzheimer's Disease in the Aging Brain. Front Aging Neurosci 10:390
Scheyer, O; Rahman, A; Hristov, H et al. (2018) Female Sex and Alzheimer's Risk: The Menopause Connection. J Prev Alzheimers Dis 5:225-230
Mosconi, Lisa; Berti, Valentina; Quinn, Crystal et al. (2017) Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. Neurology 89:1382-1390

Showing the most recent 10 out of 105 publications